Boston Scientific's strategic acquisitions and meticulous integration processes, particularly under CEO Mike Mahoney, have transformed it into a medical device giant worth $130 billion today.
What makes Boston Scientific's transformation impressive is the ability to learn from past mistakes, like the disastrous Guidant acquisition, leveraging that experience in future growth efforts.
Today, Boston Scientific's market value has skyrocketed since Mike Mahoney's appointment as CEO in 2012, symbolizing a remarkable recovery and a reinvigorated growth strategy.
The company has completed over 40 acquisitions in 12 years, showcasing a disciplined and systematic approach to integrating new businesses while fostering a culture of continuous improvement.
Collection
[
|
...
]